TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRASG12C inhibitors - PubMed
7 days ago
- #Lung Adenocarcinoma
- #Immunotherapy
- #TTF-1
- TTF-1 expression in lung adenocarcinoma (LUAD) is negative (TTF-1Neg) in 15-20% of cases, associated with worse outcomes.
- TTF-1Neg LUAD is linked to more frequent tobacco use, lower PD-L1 expression, and mutations in STK11, KEAP1, SMARCA4, NKX2-1, CDKN2A, and KRAS.
- Patients with metastatic TTF-1Neg LUAD had worse responses to immune checkpoint inhibitors, chemo-immunotherapy, durvalumab, and KRASG12C inhibitors compared to TTF-1Pos cases.
- TTF-1Neg cases showed lower objective response rates (ORR), shorter median progression-free survival (mPFS), and shorter median overall survival (mOS) across treatments.
- TTF-1 negativity identifies a subset of LUAD with poor outcomes to various therapies, including immunotherapy and KRASG12C inhibitors.